a medline for DB Karpf looks pretty good. thanks for posting this. here's some background, with note of erratum......
Cancer Res 1999 Sep 1;59(17):4200-3
Published erratum appears in Cancer Res 2000 Feb 15;60(4):1150
The addition of adenovirus type 5 region E3 enables calydon virus 787 to
eliminate distant prostate tumor xenografts.
Yu DC, Chen Y, Seng M, Dilley J, Henderson DR
Calydon, Inc., Sunnyvale, California 94089, USA.
CV787, a novel highly prostate-specific replication-competent adenovirus with improved
efficacy, was constructed. CV787 contains the prostate-specific rat probasin promoter, driving
the adenovirus type 5 (Ad5) E1A gene, and the human prostate-specific enhancer/promoter,
driving the E1B gene. To improve efficacy, we constructed CV787 such that it also contains the
entire Ad5 E3 region. CV787 replicates in prostate-specific antigen (PSA)+ cells as well as
wild-type adenovirus, but in PSA- cells, CV787 replicates 10(4)-10(5) times less efficiently.
CV787 destroys PSA+ prostate cancer cells 10,000 times more efficiently than PSA- cells.
Incorporation of the Ad5 E3 region significantly improves the target cell killing ability or efficacy
of CV787. In nu/nu mice carrying s.c. LNCaP xenografts, a single i.v. tail vein injection of
CV787 eliminates 300-mm3 tumors within 4 weeks. CV787 could be a powerful therapeutic for
human metastatic prostate cancer. |
